Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol

Circulation

Volumn 98, Issue 19, 1998, Pages 1993-1999

  Syvänne, Mikko ^a   Nieminen, Markku S ^a   Heikki Frick, M ^b   Kauma, Heikki ^a   Majahalme, Silja ^c   Virtanen, Vesa ^d   Antero Kesaniemi Y ^a   Pasternack, Amos ^a   Ehnholm, Christian ^a   Taskinen, Marja Riitta ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Angiography; Bypass; Coronary disease; Lipoproteins; Trials

Indexed keywords

CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; BLOOD VESSEL DIAMETER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DISEASE COURSE; HUMAN; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VEIN GRAFT;

EID: 0032506254     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.19.1993     Document Type: Article

References (22)

1. Schell WD, Myers JN. Regression of atherosclerosis: a review. Prog Cardiovasc Dis. 1997:39:483-496.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engt J Med. 1996;335: 1001-1009.
4. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographie assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
5. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen M-R, for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographie progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137-2143.
6. Syvänne M, Taskinen M-R, Nieminen MS, Manninen V, Kesäniemi YA, Pasternack A, Nawrocki JW, Haber H, Frick MH. A study to determine the response of coronary atherosclerosis to raising low HDL cholesterol with a fibric-acid derivative in men after coronary bypass surgery: the rationale, design, and baseline characteristics of the LOCAT study. Control Clin Trials. 1997;18:93-119.
7. Syvänne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery: a validation study. Int J Vasc Imaging. 1994; 10:243-252.
8. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 1996;93:34-41.
9. Sata T, Havel RJ, Jones AL. Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipidemic and hyperlipidemic humans. J Lipid Res. 1972;13:757-768.
10. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64:1174-1184.
11. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;5:885-888.
12. Steiner G, Schwanz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and coronary artery disease. Circulation. 1987:75:124-130.
13. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987; 2:62-66.
14. Watts GF, Mandalia S, Brunt JNH, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 1993;42:1461-1467.
15. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographie progression. Arterioscler Thromb Vasc Biol. 1996:16:697-704.
16. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographie change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990; 81:470-476.
17. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90: 42-49.
18. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vase Biol. 1997;17:715-722.
19. Hodis HN, Mack WJ, Dunn M, Liu C-r, Liu C-h, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022-2026.
20. Hodis HN. Reversibility of atherosclerosis: evolving perspectives from two arterial imaging clinical trials: the Cholesterol Lowering Atherosclerosis Regression Study and the Monitored Atherosclerosis Regression Study. J Cardiovasc Pharmacol. 1995;25(suppl 4):S25-S31.
21. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
22. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.